What is the 13F Pro Quality Score for EWTX?

13F Pro ranks Edgewise Therapeutics, Inc. (EWTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View EWTX's current score at https://13fpro.ai/research/EWTX (free sign-up required for the full ranking).

Where does 13F Pro source EWTX data?

All Edgewise Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Edgewise Therapeutics, Inc. files with the SEC under CIK 1710072. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is EWTX in?

Edgewise Therapeutics, Inc. (EWTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is EWTX research updated on 13F Pro?

EWTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Edgewise Therapeutics, Inc.(EWTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1710072 EWTX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

EWTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Edgewise Therapeutics, Inc. (EWTX), a Healthcare sector company. EWTX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Edgewise Therapeutics, Inc. reports net income of $-49.0M, free cash flow of $-42.8M. Top institutional holders of EWTX by reported 13-F value include ORBIMED ADVISORS, RA CAPITAL MANAGEMENT, L.P., Paradigm Biocapital Advisors, based on the most recent SEC filings. EWTX trades on the Nasdaq exchange and files with the SEC under CIK 1710072. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EWTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Edgewise Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-49.0M

Free Cash Flow

Q1 2026

$-42.8M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+99.9% YoY

$-133.8KFY 2024

FY21 $-42.8MFY22 $-67.6MFY23 $-100.2MFY24 $-133.8K

Operating Income

-38.9% YoY

$-158.8MFY 2024

FY21 $-43.2MFY22 $-71.7MFY23 $-114.4MFY24 $-158.8M

EPS (Diluted)

+7.6% YoY

$-1.45FY 2024

FY21 $-1.14FY22 $-1.26FY23 $-1.57FY24 $-1.45

Total Assets

+43.2% YoY

$486.8MFY 2024

FY21 $285.2MFY22 $367.1MFY23 $340.0MFY24 $486.8M

Op. Cash Flow

-18.6% YoY

$-109.0MFY 2024

FY21 $-33.5MFY22 $-52.6MFY23 $-91.9MFY24 $-109.0M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Net Income	$-133.8K +99.9%	$-100.2M -48.1%	$-67.6M -58.0%	$-42.8M -150.0%	$-17.1M	—
Operating Income	$-158.8M -38.9%	$-114.4M -59.6%	$-71.7M -65.8%	$-43.2M -151.4%	$-17.2M	—
EPS (Diluted)	$-1.45 +7.6%	$-1.57 -24.6%	$-1.26 -10.5%	$-1.14 +95.1%	$-23.17	—
Total Assets	$486.8M +43.2%	$340.0M -7.4%	$367.1M +28.7%	$285.2M +117.5%	$131.1M	—
Operating Cash Flow	$-109.0M -18.6%	$-91.9M -74.7%	$-52.6M -57.1%	$-33.5M -129.0%	$-14.6M	—

AI Insight: EWTX Financial Trends

Edgewise remains deeply unprofitable with accelerating operating losses and deteriorating cash burn; equity cushion eroding steadily.

• Operating income worsened from -$38M in Q2 2024 to -$54M in Q1 2026, a 42% deterioration over 8 quarters.

• Operating cash burn intensified to -$43M in Q1 2026 from -$26M in Q2 2024; no revenue reported across all periods.

• Equity declined 3% from $510M to $493M over 8 quarters as cumulative losses compound without offsetting revenue.

⚠ Q1 2026 operating loss of -$54M is the worst on record; if sustained, equity runway is ~9 quarters at current burn.

⚠ Absence of revenue across entire dataset indicates pre-commercial or failed pipeline; no path to positive cash generation visible.

AI Insight: EWTX Ratio Trends

EWTX remains unprofitable with deteriorating returns; ROIC worsened to -43.9% in Q1 2026, the lowest in the dataset.

• ROIC declined from -40.5% (TTM) to -43.9% (Q1 2026), extending a secular downtrend since Q2 2024 (-29.9%).

• ROE and ROA mirrored ROIC deterioration, both hitting worst levels at -39.8% and -37.8% in Q1 2026 respectively.

• Quarterly returns show cyclical swings (Q2 2025 improved to -28.9% ROIC, but Q1 2026 dropped again to -43.9%).

⚠ Q1 2026 marks the worst ROIC quarter on record; trend reversal required to signal operational inflection.

⚠ Persistent negative returns across all profitability metrics; path to breakeven and positive capital returns unclear.

Get alerted when EWTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Edgewise Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of EWTX

ORBIMED ADVISORS LLC
$488.8M15,518,492 sh
RA CAPITAL MANAGEMENT, L.P.
$328.5M10,428,437 sh
Paradigm Biocapital Advisors LP
$232.0M7,365,038 sh
BAKER BROS. ADVISORS LP
$207.1M6,575,940 sh
BlackRock, Inc.
$203.9M6,472,991 sh
JANUS HENDERSON GROUP PLC
$186.3M5,915,556 sh
Novo Holdings A/S
$168.5M5,350,000 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$141.1M4,477,942 sh
Siren, L.L.C.
$139.6M4,430,263 sh
PERCEPTIVE ADVISORS LLC
$139.4M4,423,974 sh

Fund	Value	Shares
ORBIMED ADVISORS LLC	$488.8M	15,518,492
RA CAPITAL MANAGEMENT, L.P.	$328.5M	10,428,437
Paradigm Biocapital Advisors LP	$232.0M	7,365,038
BAKER BROS. ADVISORS LP	$207.1M	6,575,940
BlackRock, Inc.	$203.9M	6,472,991
JANUS HENDERSON GROUP PLC	$186.3M	5,915,556
Novo Holdings A/S	$168.5M	5,350,000
DRIEHAUS CAPITAL MANAGEMENT LLC	$141.1M	4,477,942
Siren, L.L.C.	$139.6M	4,430,263
PERCEPTIVE ADVISORS LLC	$139.4M	4,423,974

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put EWTX on your watchlist

Track score changes the day Edgewise Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is EWTX a good stock to buy?

13F Pro's AI-powered analysis of Edgewise Therapeutics, Inc. (EWTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EWTX are available on the EWTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own EWTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EWTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Edgewise Therapeutics, Inc.'s investment landscape.